REIT - Specialty
Compare Stocks
5 / 10Stock Comparison
CXW vs WELL vs ENSG vs VTR vs UHS
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Healthcare Facilities
Medical - Care Facilities
REIT - Healthcare Facilities
Medical - Care Facilities
CXW vs WELL vs ENSG vs VTR vs UHS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | REIT - Specialty | REIT - Healthcare Facilities | Medical - Care Facilities | REIT - Healthcare Facilities | Medical - Care Facilities |
| Market Cap | $2.16B | $149.25B | $10.18B | $41.15B | $10.68B |
| Revenue (TTM) | $2.34B | $11.63B | $5.27B | $6.13B | $17.76B |
| Net Income (TTM) | $129M | $1.43B | $363M | $260M | $1.52B |
| Gross Margin | 23.6% | 39.1% | 15.2% | -4.3% | 67.6% |
| Operating Margin | 14.7% | 4.4% | 8.5% | 13.4% | 11.5% |
| Forward P/E | 14.4x | 78.4x | 23.2x | 118.0x | 7.3x |
| Total Debt | $1.22B | $21.38B | $4.15B | $13.22B | $5.51B |
| Cash & Equiv. | $112M | $5.03B | $504M | $741M | $138M |
CXW vs WELL vs ENSG vs VTR vs UHS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CoreCivic, Inc. (CXW) | 100 | 181.3 | +81.3% |
| Welltower Inc. (WELL) | 100 | 420.4 | +320.4% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
| Ventas, Inc. (VTR) | 100 | 247.6 | +147.6% |
| Universal Health Se… (UHS) | 100 | 161.7 | +61.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CXW vs WELL vs ENSG vs VTR vs UHS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CXW lags the leaders in this set but could rank higher in a more targeted comparison.
WELL carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 35.8%, EPS growth -11.5%, 3Y rev CAGR 22.7%
- 223.1% 10Y total return vs ENSG's 7.5%
- Lower volatility, beta 0.13, Low D/E 49.5%, current ratio 5.34x
- Beta 0.13, yield 1.3%, current ratio 5.34x
Among these 5 stocks, ENSG doesn't own a clear edge in any measured category.
VTR is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 1 yrs, beta 0.01, yield 2.1%
- Beta 0.01 vs CXW's 0.61
- 2.1% yield, 1-year raise streak, vs ENSG's 0.1%, (1 stock pays no dividend)
UHS ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.46 vs ENSG's 1.68
- Lower P/E (7.3x vs 118.0x)
- 9.8% ROA vs VTR's 1.0%, ROIC 12.3% vs 2.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 35.8% FFO/revenue growth vs UHS's 9.7% | |
| Value | Lower P/E (7.3x vs 118.0x) | |
| Quality / Margins | 12.3% margin vs VTR's 4.2% | |
| Stability / Safety | Beta 0.01 vs CXW's 0.61 | |
| Dividends | 2.1% yield, 1-year raise streak, vs ENSG's 0.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +42.7% vs UHS's -8.2% | |
| Efficiency (ROA) | 9.8% ROA vs VTR's 1.0%, ROIC 12.3% vs 2.5% |
CXW vs WELL vs ENSG vs VTR vs UHS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CXW vs WELL vs ENSG vs VTR vs UHS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UHS leads in 2 of 6 categories
WELL leads 1 • VTR leads 1 • CXW leads 0 • ENSG leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — CXW and WELL each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UHS is the larger business by revenue, generating $17.8B annually — 7.6x CXW's $2.3B. WELL is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to VTR's 4.2%. On growth, WELL holds the edge at +40.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.3B | $11.6B | $5.3B | $6.1B | $17.8B |
| EBITDAEarnings before interest/tax | $475M | $2.8B | $558M | $2.3B | $2.7B |
| Net IncomeAfter-tax profit | $129M | $1.4B | $363M | $260M | $1.5B |
| Free Cash FlowCash after capex | $49M | $2.5B | $406M | $1.4B | $894M |
| Gross MarginGross profit ÷ Revenue | +23.6% | +39.1% | +15.2% | -4.3% | +67.6% |
| Operating MarginEBIT ÷ Revenue | +14.7% | +4.4% | +8.5% | +13.4% | +11.5% |
| Net MarginNet income ÷ Revenue | +5.5% | +12.3% | +6.9% | +4.2% | +8.6% |
| FCF MarginFCF ÷ Revenue | +2.1% | +21.9% | +7.7% | +22.4% | +5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.8% | +40.3% | +18.4% | +22.0% | +9.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.5% | +22.5% | +21.9% | 0.0% | +17.7% |
Valuation Metrics
UHS leads this category, winning 7 of 7 comparable metrics.
Valuation Metrics
At 7.4x trailing earnings, UHS trades at a 95% valuation discount to VTR's 160.3x P/E. Adjusting for growth (PEG ratio), UHS offers better value at 0.46x vs ENSG's 2.16x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.2B | $149.2B | $10.2B | $41.1B | $10.7B |
| Enterprise ValueMkt cap + debt − cash | $3.3B | $165.6B | $13.8B | $53.6B | $16.0B |
| Trailing P/EPrice ÷ TTM EPS | 20.19x | 153.25x | 29.85x | 160.26x | 7.38x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.44x | 78.42x | 23.19x | 118.01x | 7.30x |
| PEG RatioP/E ÷ EPS growth rate | 1.06x | — | 2.16x | — | 0.46x |
| EV / EBITDAEnterprise value multiple | 6.83x | 66.40x | 25.71x | 24.31x | 6.14x |
| Price / SalesMarket cap ÷ Revenue | 0.98x | 13.99x | 2.01x | 7.05x | 0.61x |
| Price / BookPrice ÷ Book value/share | 1.67x | 3.35x | 4.59x | 3.18x | 1.48x |
| Price / FCFMarket cap ÷ FCF | 39.96x | 52.41x | 27.46x | 31.25x | 12.57x |
Profitability & Efficiency
UHS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UHS delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $2 for VTR. WELL carries lower financial leverage with a 0.49x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), CXW scores 7/9 vs ENSG's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.0% | +3.5% | +16.6% | +2.1% | +20.7% |
| ROA (TTM)Return on assets | +4.0% | +2.3% | +6.8% | +1.0% | +9.8% |
| ROICReturn on invested capital | +10.7% | +0.5% | +7.0% | +2.5% | +12.3% |
| ROCEReturn on capital employed | +12.6% | +0.6% | +10.2% | +3.2% | +16.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 | 5 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.87x | 0.49x | 1.86x | 1.05x | 0.74x |
| Net DebtTotal debt minus cash | $1.1B | $16.3B | $3.7B | $12.5B | $5.4B |
| Cash & Equiv.Liquid assets | $112M | $5.0B | $504M | $741M | $138M |
| Total DebtShort + long-term debt | $1.2B | $21.4B | $4.2B | $13.2B | $5.5B |
| Interest CoverageEBIT ÷ Interest expense | 3.53x | 0.26x | 88.33x | 1.40x | 10.92x |
Total Returns (Dividends Reinvested)
WELL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WELL five years ago would be worth $30,234 today (with dividends reinvested), compared to $11,248 for UHS. Over the past 12 months, WELL leads with a +42.7% total return vs UHS's -8.2%. The 3-year compound annual growth rate (CAGR) favors WELL at 42.5% vs UHS's 6.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.7% | +14.3% | +0.3% | +12.6% | -22.3% |
| 1-Year ReturnPast 12 months | -3.5% | +42.7% | +27.5% | +33.9% | -8.2% |
| 3-Year ReturnCumulative with dividends | +135.0% | +189.5% | +88.9% | +94.2% | +20.8% |
| 5-Year ReturnCumulative with dividends | +167.9% | +202.3% | +103.2% | +74.8% | +12.5% |
| 10-Year ReturnCumulative with dividends | -13.4% | +223.1% | +752.0% | +65.0% | +30.8% |
| CAGR (3Y)Annualised 3-year return | +33.0% | +42.5% | +23.6% | +24.8% | +6.5% |
Risk & Volatility
VTR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
VTR is the less volatile stock with a 0.01 beta — it tends to amplify market swings less than CXW's 0.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VTR currently trades 97.8% from its 52-week high vs UHS's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 0.13x | 0.42x | 0.01x | 0.60x |
| 52-Week HighHighest price in past year | $23.54 | $219.59 | $218.00 | $88.50 | $246.33 |
| 52-Week LowLowest price in past year | $15.74 | $142.65 | $133.81 | $61.76 | $152.33 |
| % of 52W HighCurrent price vs 52-week peak | +92.7% | +97.0% | +80.0% | +97.8% | +69.2% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 60.2 | 23.3 | 56.2 | 39.7 |
| Avg Volume (50D)Average daily shares traded | 993K | 2.6M | 358K | 3.4M | 793K |
Analyst Outlook
Evenly matched — ENSG and VTR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CXW as "Buy", WELL as "Buy", ENSG as "Buy", VTR as "Buy", UHS as "Hold". Consensus price targets imply 35.7% upside for UHS (target: $232) vs -28.9% for CXW (target: $16). For income investors, VTR offers the higher dividend yield at 2.15% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $15.50 | $226.50 | $222.33 | $90.80 | $231.50 |
| # AnalystsCovering analysts | 12 | 34 | 13 | 32 | 43 |
| Dividend YieldAnnual dividend ÷ price | +0.0% | +1.3% | +0.1% | +2.1% | +0.5% |
| Dividend StreakConsecutive years of raises | 0 | 2 | 12 | 1 | 1 |
| Dividend / ShareAnnual DPS | $0.00 | $2.76 | $0.24 | $1.86 | $0.80 |
| Buyback YieldShare repurchases ÷ mkt cap | +10.6% | 0.0% | +0.2% | 0.0% | +9.1% |
UHS leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). WELL leads in 1 (Total Returns). 2 tied.
CXW vs WELL vs ENSG vs VTR vs UHS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CXW or WELL or ENSG or VTR or UHS a better buy right now?
For growth investors, Welltower Inc.
(WELL) is the stronger pick with 35. 8% revenue growth year-over-year, versus 9. 7% for Universal Health Services, Inc. (UHS). Universal Health Services, Inc. (UHS) offers the better valuation at 7. 4x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate CoreCivic, Inc. (CXW) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CXW or WELL or ENSG or VTR or UHS?
On trailing P/E, Universal Health Services, Inc.
(UHS) is the cheapest at 7. 4x versus Ventas, Inc. at 160. 3x. On forward P/E, Universal Health Services, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Universal Health Services, Inc. wins at 0. 46x versus The Ensign Group, Inc. 's 1. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — CXW or WELL or ENSG or VTR or UHS?
Over the past 5 years, Welltower Inc.
(WELL) delivered a total return of +202. 3%, compared to +12. 5% for Universal Health Services, Inc. (UHS). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus CXW's -13. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CXW or WELL or ENSG or VTR or UHS?
By beta (market sensitivity over 5 years), Ventas, Inc.
(VTR) is the lower-risk stock at 0. 01β versus CoreCivic, Inc. 's 0. 61β — meaning CXW is approximately 6301% more volatile than VTR relative to the S&P 500. On balance sheet safety, Welltower Inc. (WELL) carries a lower debt/equity ratio of 49% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CXW or WELL or ENSG or VTR or UHS?
By revenue growth (latest reported year), Welltower Inc.
(WELL) is pulling ahead at 35. 8% versus 9. 7% for Universal Health Services, Inc. (UHS). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -11. 5% for Welltower Inc.. Over a 3-year CAGR, WELL leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CXW or WELL or ENSG or VTR or UHS?
Welltower Inc.
(WELL) is the more profitable company, earning 8. 8% net margin versus 4. 3% for Ventas, Inc. — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CXW leads at 15. 8% versus 3. 3% for WELL. At the gross margin level — before operating expenses — UHS leads at 90. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CXW or WELL or ENSG or VTR or UHS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Universal Health Services, Inc. (UHS) is the more undervalued stock at a PEG of 0. 46x versus The Ensign Group, Inc. 's 1. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Universal Health Services, Inc. (UHS) trades at 7. 3x forward P/E versus 118. 0x for Ventas, Inc. — 110. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for UHS: 35. 7% to $231. 50.
08Which pays a better dividend — CXW or WELL or ENSG or VTR or UHS?
In this comparison, VTR (2.
1% yield), WELL (1. 3% yield), UHS (0. 5% yield), ENSG (0. 1% yield) pay a dividend. CXW does not pay a meaningful dividend and should not be held primarily for income.
09Is CXW or WELL or ENSG or VTR or UHS better for a retirement portfolio?
For long-horizon retirement investors, Ventas, Inc.
(VTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 01), 2. 1% yield). Both have compounded well over 10 years (VTR: +65. 0%, CXW: -13. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CXW and WELL and ENSG and VTR and UHS?
These companies operate in different sectors (CXW (Real Estate) and WELL (Real Estate) and ENSG (Healthcare) and VTR (Real Estate) and UHS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CXW is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; ENSG is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; UHS is a mid-cap deep-value stock. WELL, VTR pay a dividend while CXW, ENSG, UHS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.